Here are some updates on drug research and technology from my reading-
Newer research pathways for Alzheimer's drug development -
Big drug companies since the 1990s have bet heavily on the concept that amyloid poisons brain cells and that blocking it will halt a patient's devastating decline" in Alzheimer's disease, but "even as their drugs move into final human trials, the evidence implicating amyloid is starting to look a little shaky.
Research indicates Rituxan may increase progression-free survival in patients with follicular lymphoma-
Roche Holding AG unit Genentech Inc and Biogen Idec . announced that Rituxan (rituximab) increased progression-free survival when taken alone by patients with follicular lymphoma who previously responded to Rituxan and chemotherapy together.
A longer period of preventive treatment after kidney transplant can help reduce the risk that the patient will become infected with cytomegalovirus (CMV)-
A Sept. 17 online publication of Journal of the American Society of Nephrology states, a longer period of preventive treatment after kidney transplant can help reduce the risk that the patient will become infected with cytomegalovirus (CMV). CMV disease increases the risk of morbidity, rehospitalization, and death after transplants, particularly those of the kidney.
Newer research pathways for Alzheimer's drug development -
Big drug companies since the 1990s have bet heavily on the concept that amyloid poisons brain cells and that blocking it will halt a patient's devastating decline" in Alzheimer's disease, but "even as their drugs move into final human trials, the evidence implicating amyloid is starting to look a little shaky.
Research indicates Rituxan may increase progression-free survival in patients with follicular lymphoma-
Roche Holding AG unit Genentech Inc and Biogen Idec . announced that Rituxan (rituximab) increased progression-free survival when taken alone by patients with follicular lymphoma who previously responded to Rituxan and chemotherapy together.
A longer period of preventive treatment after kidney transplant can help reduce the risk that the patient will become infected with cytomegalovirus (CMV)-
A Sept. 17 online publication of Journal of the American Society of Nephrology states, a longer period of preventive treatment after kidney transplant can help reduce the risk that the patient will become infected with cytomegalovirus (CMV). CMV disease increases the risk of morbidity, rehospitalization, and death after transplants, particularly those of the kidney.
